Surface marker modification of fibroblasts to target cells to specific tissue and organs for therapeutic use
WO2026085031A3 Publication Date: 2026-05-28FIBROBIOLOGICS INC
3 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2025/050736
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-14
- Filing Date
- 2025-10-13
- Publication Date
- 2026-05-28
AI Technical Summary
Technical Problem
Current small molecule and antibody-based therapeutics have off-target effects leading to significant side effects, and invasive stem cell administration methods hinder patient compliance and utilization in tissue regeneration.
Method used
Modify fibroblasts and fibroblast-derived materials with CRISPR/CAS9 and other gene editing technologies to target specific tissues or organs, allowing for targeted administration of modified fibroblasts, exosomes, and other products for tissue repair, immune modulation, and stem cell niche activation.
Benefits of technology
Achieves targeted delivery of fibroblasts and derivatives to specific tissues, reducing off-target effects and improving patient compliance by enabling precise tissue regeneration and immune modulation.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure concerns genetic modification of fibroblasts or fibroblast-derived materials (including of the fibroblasts from which the fibroblast-derived materials are derived). In specific aspects, they are modified such that they may express one or more surface markers that allow targeting to a tissue and / or organ of interest. In some aspects, they are modified such that they may lose one or more surface markers that then allow targeting to a tissue and / or organ of interest. In certain aspects, one or more surface markers are modified that then allows targeting to a tissue and / or organ of interest.
Need to check novelty before this filing date? Find Prior Art